New developments in the treatment of ovarian cancer—future perspectives
Open Access
- 1 December 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (suppl_10) , x69-x76
Abstract
Over the past 40 years, the treatment of ovarian cancer has undoubtedly improved as a result of better multi-modality care and platinum-based chemotherapy. More recently, the introduction of anti-angiogenic therapy, PARP inhibitors and a weekly regimen for paclitaxel indicate that results are likely to improve further. However, major challenges remain and these will be reviewed in this article. We assess key issues in anti-angiogenic treatment including potential ways for addressing resistance; we review the current studies of PARP inhibitor treatment, which shows most promise in patients with germline BRCA mutations; we describe the potential for folate-receptor-directed therapy, given the high level of FR expression in ovarian cancer and we highlight the potential for molecular targeted therapy, focusing on specific subgroups of the disease with targets such as the PI3 K/AKT and RAS/RAF/MEK pathways and the ErbB family of oncogenes. We anticipate that progress will accelerate with a better understanding of the molecular pathogenesis of the various subtypes of ovarian cancer, leading to an increasingly personalized approach to treating women with this disease.Keywords
Funding Information
- National Institute of Health Research
- NIHR
- Biomedical Research Centre
- Cancer Research UK
This publication has 100 references indexed in Scilit:
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- The role of PARP in DNA repair and its therapeutic exploitationBritish Journal of Cancer, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Regulation of Tumor Angiogenesis by EZH2Cancer Cell, 2010
- Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapiesGynecologic Oncology, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- The Hallmarks of CancerCell, 2000